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Abstract
BACKGROUND—There is increasing need for better therapies to prevent the development of 
heart failure after myocardial infarction (MI). An injectable hydrogel derived from decellularized 
porcine ventricular myocardium has been shown to halt the post-infarction progression of negative 
left ventricular remodeling and decline in cardiac function in both small and large animal models.
OBJECTIVES—We sought to elucidate the tissue level mechanisms underlying the therapeutic 
benefits of myocardial matrix injection.
METHODS—Myocardial matrix or saline was injected into infarcted myocardium 1 week after 
ischemia-reperfusion in Sprague Dawley rats. Cardiac function was evaluated by magnetic 
resonance imaging and hemodynamic measurements at 5 weeks post-injection. Whole 
transcriptome microarrays were performed on ribonucleic acid (RNA) isolated from the infarct at 
3 days and 1 week after injection. Quantitative polymerase chain reaction and histological 
quantification confirmed expression of key genes and their activation in altered pathways.
RESULTS—Principal component analysis of the transcriptomes showed that samples collected 
from myocardial matrix-injected infarcts are distinct and cluster separately from saline-injected 
controls. Pathway analysis indicated that these differences are due to changes in several tissue 
processes that may contribute to improved cardiac healing post-MI. Matrix-injected infarcted 
myocardium exhibits an altered inflammatory response, reduced cardiomyocyte apoptosis, 
enhanced infarct neovascularization, diminished cardiac hypertrophy and fibrosis, altered 
metabolic enzyme expression, increased cardiac transcription factor expression, and progenitor 
cell recruitment, along with improvements in global cardiac function and hemodynamics.
Address for correspondence: Karen L. Christman, PhD, 2880 Torrey Pines Scenic Drive, La Jolla, California 92037, Telephone: 
(858) 822-7863, Fax: (858) 534-5722, christman@eng.ucsd.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered 
which could affect the content, and all legal disclaimers that apply to the journal pertain.
Disclosures: The other authors have nothing to disclose
HHS Public Access
Author manuscript
J Am Coll Cardiol. Author manuscript; available in PMC 2017 March 08.
Published in final edited form as:
J Am Coll Cardiol. 2016 March 8; 67(9): 1074–1086. doi:10.1016/j.jacc.2015.12.035.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
CONCLUSIONS—These results indicate that the myocardial matrix alters several key pathways 
post-MI creating a pro-regenerative environment, further demonstrating its promise as a potential 
post-MI therapy.
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Progression from acute myocardial infarction (MI) to chronic heart failure (HF) begins with 
an initial ischemic injury, resulting in progressive myocyte loss through both necrotic and 
apoptotic mechanisms, and migration of inflammatory cells into the injured myocardium. 
An increase in matrix metalloproteinases (MMP) from the inflammatory infiltrate further 
exacerbates the decline in heart function by digesting the extracellular matrix (ECM), 
followed by subsequent deposition of fibrillar cross-linked collagen. The heart has recently 
been recognized as an organ capable of some degree of self-regeneration (1). However, this 
is insufficient to compensate for the billions of cardiomyocytes lost after MI (2). 
Additionally, function of surviving cardiomyocytes is also altered post-infarction. The heart 
has a high energy demand and recent studies have shown that dysregulation in cardiac 
metabolism post-MI contributes notably to cardiac dysfunction in HF (3).
Interest in developing alternative treatments for MI has been expanding. Such therapies 
include various cells, biological molecules, acellular biomaterials, or combinations thereof. 
Meta-analyses of initial cell therapy trials suggest only a modest effect on cardiac function 
(4), and given low cell survival rates and their largely paracrine mechanism of action, there 
has been increasing interest in the use of injectable acellular scaffolds (5). If designed 
appropriately, these biomaterials can be delivered through minimally invasive approaches 
and stimulate cardiac repair, while avoiding many of the complications associated with a 
living product (6). Our group previously developed an injectable myocardial matrix 
hydrogel, derived from decellularized porcine ventricular ECM (7), which can be delivered 
with a transendocardial catheter. This hydrogel was shown to reduce negative left 
ventricular (LV) remodeling and the decline in cardiac function in both rat (8) and pig (9) 
models when delivered 2 weeks post-MI. Herein, we examined whether the material could 
improve global cardiac function and hemodynamics when delivered 1 week post-MI in a rat 
model, and utilized a transcriptomics-directed approach to identify the underlying 
mechanisms by which the matrix improves post-MI repair.
METHODS
All procedures in this study were approved by the Committee on Animal Research at the 
University of California, San Diego and the Association for the Assessment and 
Accreditation of Laboratory Animal Care. Myocardial matrix or saline was injected into the 
area of ischemia 1 week after 25 minutes of ischemia-reperfusion in female Sprague-Dawley 
rats. Rat Gene 2.0 ST arrays (Affymetrix, Inc., Santa Clara, California) were used for whole 
transcriptome analysis of infarct and border zone at 3 days and 1 week post-injection, 
followed by validation of the expression of key genes by quantitative real-time polymerase 
chain reaction (qPCR). Cardiac magnetic resonance imaging (CMR) and hemodynamics 
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recordings were performed at 5 weeks post-injection (6 weeks post-MI). Histology and 
immunohistochemistry (IHC) were used to quantify phenotypic changes. For further details, 
refer to the Online Appendix.
RESULTS
CARDIAC FUNCTION
Myocardial matrix injection (n = 8) significantly reduced the percent change in ejection 
fraction (p = 0.028) and end-systolic volume (p = 0.004) compared to saline (n = 7) (Figure 
1A) from 6 days post-MI (1 day prior to injection) to 6 weeks post-MI (5 weeks post-
injection). There was a similar but nonsignificant trend for end-diastolic volume (p = 0.11). 
CMR data are provided in Online Table 1. LV hemodynamics were measured using a 
microtipped manometer pressure catheter at 6 weeks post-MI (Figure 1B). Compared to 
saline (n = 5), myocardial matrix-injected hearts (n = 5) had significantly higher LV peak 
systolic pressure (p = 0.002), myocardial relaxation (–dP/dtmax; p = 0.003), and myocardial 
contractility (+dP/dtmax; p = 0.002).
TRANSCRIPTOMICS
Differences in transcriptomes between saline- and matrix-treated infarcts were globally 
examined using both principal component analysis (PCA) and hierarchical clustering. 
Saline- and myocardial matrix-injected samples did not cluster separately at 3 days post-
injection. However, by 1 week post-injection, both PCA (Figure 2A) and hierarchical 
clustering (Figures 2B and 2C) showed separation of the transcriptomes (p = 0.06), 
indicating a shift in global gene expression. A false discovery rate of q < 0.05 was used to 
determine the differentially expressed genes for biological interpretation (Online Table 2). A 
Panther overrepresentation test showed that differences in transcripts from ECM (GO: 
0031012 by Gene Ontology [GO]) and those responsible for muscle contraction (GO:
006936) for the 1-week time point were nonsignificant (p = 0.37 and p = 0.88, respectively), 
indicating that differences in gene expression were not due to sampling variability. Using 
Ingenuity® Pathway Analysis (IPA) (Qiagen, Redwood City, California), we identified the 
main effects of the myocardial matrix at 3 days post-injection as downregulation of 
apoptosis, upregulation of blood vessel development, and increase in cell movement (Online 
Table 3). By 1 week, several pathways were significantly activated, including 
downregulation of cell death and hypertrophy, and upregulation of many metabolic 
processes and gene translation/transcription (Online Table 4). Based on the differences 
elucidated by this transcriptome analysis, we performed qPCR on key genes in the identified 
pathways (Online Figure 1) and further assessed differences at the tissue level using IHC as 
described later.
INFLAMMATORY RESPONSE
Pathways involved in the immune response including migration and infiltration of various 
cell types were predicted at both the 3-day and 1-week time points (Online Tables 3 and 4, 
Figure 3A, and Online Figure 2). Similarly, a substantial number of genes at both time 
points – 26.6% at day 3 and 9.8% at 1 week – were characterized as part of immune 
response process (GO:0002376). Increased expression of CD68 (p = 0.045) and MMP12 (p 
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= 0.043) (Online Figure 1A) were confirmed by qPCR, indicative of increased macrophage 
infiltration as a result of matrix injection, yet IHC analysis using a CD68 antibody (Figure 
3B) did not show a difference in macrophage infiltration between saline- and matrix-injected 
infarcts at 3 days (Figure 3C). There was, however, a trend towards an increase in 
infiltrating tryptase+ mast cells (Figure 3D) at 3 days (p = 0.052), which reached 
significance by 1 week (p = 0.032) (Figure 3E).
BLOOD VESSEL FORMATION
Activation of blood vessel development was predicted by IPA at 3 days post-injection 
(Online Table 3 and Figure 4A). While increased vessel development was not directly 
predicted at 1 week post-injection, many growth factors associated with angiogenesis and 
neovascularization were identified (Figure 4A). These included a decrease in angiopoietin-2 
(p = 0.012) and increases in acidic fibroblast growth factor (p = 0.053) and vascular 
endothelial growth factors A and B (p = 0.034 and p = 0.009 respectively), confirmed by 
qPCR (Online Figure 1B). Infarct vascularization was then examined by IHC (Figure 4B). 
While not significantly different at 3 days post-injection, capillary density was significantly 
higher in the matrix-injected group at 1 week (p = 0.038) (Figure 4C). Arteriole density 
showed a similar result, with no difference at 3 days, but a trend towards an increase at 1 
week in the matrix group (p = 0.056) (Figure 4D). When subdivided into large (Online 
Figure 3A), medium (Online Figure 3B), and small (Online Figure 3C) arterioles, there was 
a trend at 3 days for increased small arterioles within matrix-injected infarcts (p = 0.082), 
which shifted at 1 week to a significant increase in medium (p = 0.021) and a trend for an 
increase in large diameter vessels (p = 0.065).
CARDIOMYOCYTE APOPTOSIS
Decreased apoptosis was consistently predicted by IPA at both 3 days and 1 week post-
injection (Online Tables 3 and 4, Figure 5A, and Online Figures 4 and 5). Increased 
expression of antioxidative enzymes heme oxygenase 1 (p = 0.015) at 3 days and catalase (p 
= 0.002) at 1 week, as well as the antiapoptosis regulator Bcl-2 (p = 0.006) at 1 week, were 
confirmed using qPCR (Online Figure 1C). To determine the effect myocardial matrix 
injection may have on apoptosis of cardiomyocytes specifically, anti-cleaved-Caspase3 
staining with colabeling of cardiomyocytes using α-actinin was performed (Figure 5B). 
Quantification of the number of caspase-3-expressing cardiomyocytes within the infarct wall 
showed a trend towards decreased apoptotic cardiomyocytes within the infarct wall (p = 
0.085) at 3 days post-injection (Figure 5C).
CARDIAC METABOLISM
At 1 week post-injection, several genes associated with oxidative metabolism and 
mitochondrial biogenesis were upregulated and predicted to be activated by IPA (Online 
Table 4, Figure 6A, and Online Figures 6 and 7). Similarly, GO analysis classified 53% of 
the differentially expressed transcripts to be involved in metabolic processes (GO:008152). 
Within these genes, we identified several upregulated nuclear receptors involved in cardiac 
metabolism and mitochondrial biogenesis, including increased expression of the 
transcription co-activator peroxisome proliferator-activated receptor (PPAR) gamma 
coactivator 1-alpha (PGC-1α) (p = 0.006) and several of its target receptors, including 
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estrogen-related receptor (ERR) γ (p = 0.001) and PPARα (p = 0.032) and β/δ (p = 0.018), 
which were confirmed by qPCR (Online Figure 1D). To determine whether changes in 
metabolism were specifically associated with cardiomyocytes, IHC was performed to 
identify expression of PGC-1α within cardiomyocytes (Figure 6B). Quantification of 
PGC-1α+ cardiomyocytes adjacent to the infarct scar revealed that myocardial matrix-
injected hearts exhibited a higher percentage of PGC-1α expression compared to saline-
injected hearts (p = 0.009) (Figure 6C).
CARDIAC DEVELOPMENT AND PROGENITORS
Review of significant GO terms showed several associated with muscle development, 
including heart development (GO:0007507; Figure 7A), and qPCR-confirmed consistent 
elevated expression of GATA4 (p = 0.022), Nkx2.5 (p = 0.009), MEF2d (p = 0.004), 
myocardin (p = 0.004), Tbx5 (p = 0.012), and Tbx20 (p = 0.043) (Online Figure 1E). We 
also assessed infiltration of cells expressing cKit, a commonly used marker for cardiac 
progenitor cells (CPCs). Since cKit is also expressed by mast cells, tissue sections were 
costained with antimast cell tryptase (Figure 7B). Quantification of cKit+/tryptase-cells in 
the infarct wall showed a trend at 3 days (p = 0.067), which reached significance at 1 week 
(p = 0.031) in the matrix-injected group (Figure 7C). Costaining showed some of these cells 
expressed the cardiac transcription factor Nkx2.5 (Online Figure 8).
HYPERTROPHY AND FIBROSIS
At 1 week post-injection, cardiac hypertrophy was highly represented in the pathways 
predicted to be downregulated by IPA (Online Table 4, Figure 8A, and Online Figure 9). 
Increased expression of negative regulators of hypertrophy DUSP5 (p = 0.003) and 
DYRK1a (p = 0.004) as well as a decrease in the positive regulator NUPR1 (p = 0.048) were 
all confirmed by qPCR (Online Figure 1F). The effects on hypertrophic LV remodeling 
were therefore assessed at 5 weeks post-injection by measuring cardiomyocyte diameter to 
evaluate cardiomyocyte hypertrophy (Figure 8B) and staining with Mason’s trichrome to 
evaluate interstitial fibrosis in the remote myocardium. Quantification of cross-sectional 
areas showed a trend in the matrix-injected hearts (n = 7) toward less hypertrophic 
cardiomyocytes (p = 0.061) (Figure 8C) compared to saline (n = 8). Moreover, myocardial 
matrix injection was associated with significantly reduced interstitial fibrosis (p < 0.001) 
(Figure 8D).
DISCUSSION
Previous small and large animal studies have demonstrated that injection of acellular 
myocardial matrix improved cardiac function and reduced negative LV remodeling when 
delivered 2 weeks post-MI. Importantly, biocompatibility, hemocompatibility, and lack of 
arrhythmias were demonstrated (8,9). In the current study, we analyzed infarct gene 
expression using wholetranscriptome microarrays to gain a comprehensive understanding of 
the tissue-level mechanism of action of the myocardial matrix hydrogel. Gene expression 
was analyzed at both 3 days and 1 week post-injection based on previous studies indicating 
that cellular infiltration into the injected hydrogel was most pronounced during the first 
week (9). By 1 week post-injection, the transcriptomes of saline and matrix-injected infarcts 
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clustered separately. Similar analyses have also been applied to other experimental therapies 
for MI including cell transplantation (10–12) and injection of cell-derived products (13); 
however, to our knowledge, no other biologic-based therapy has been reported to induce a 
distinct transcription signature at a global level. In this study, the key modulated pathways 
included inflammation, reduction of apoptosis and cardiac hypertrophy, metabolism, and 
blood vessel and cardiac development (Central Illustration).
Gene expression differences within the infarct suggested an increase in macrophage 
migration in response to the matrix injection with increased transcription of CD68, a 
macrophage marker, and MMP12, a macrophage-specific protease (14). However, 
differences in transcription patterns could also be attributed to changes in immune cell 
behavior since an increase in macrophages was not demonstrated. Collective analysis of all 
differentially expressed transcripts related to inflammation was not conclusive regarding 
whether there was a predominance of either M1 or M2 macrophage activation, which has 
been attributed to pro-inflammatory and proremodeling responses, respectively (15). Both 
phenotypes are likely necessary for post-infarct repair as depletion of either M1 or M2 
macrophages inhibited the ability of neonatal hearts to regenerate post-MI (16). In the 
process of identifying c-Kit+ progenitors, which stain negative for tryptase, we detected a 
notable increase in the number of tryptase+ mast cells in the matrix-injected groups. While 
mast cells are traditionally associated with an allergic response, they are also involved in 
neovascularization and regulation of the immune response (17). Following ischemia, rapid 
mast cell degranulation occurs, triggering recruitment of other leukocytes and preventing 
cardiomyocyte apoptosis (18). Additionally, mast cell products are known to be inherently 
angiogenic and stimulate endothelial secretion of angiogenic chemokines (19). While it is 
known that mast cell activation may be the first step in the acute inflammatory response to 
implanted biomaterials (20), implication on the reparative response of decellularized 
materials has not been reported.
By 1 week post-injection, myocardial matrix had also significantly increased infarct 
neovasculature. Interestingly, the changes over time appeared to be due to a decrease in 
endothelial cells and arterioles in the saline-injected controls. Immediately post-MI, 
hypoxia-inducible factor expression triggers transcriptional activation of many angiogenic 
factors (21); however, a decrease in vascular density with time has been previously reported 
(22), possibly due to vessel regression. Notably, 1 factor known to induce this process is 
angiopoietin 2, which was more highly expressed in the saline group compared to the 
matrix. Preservation of the infarct vasculature may be a result of the pro-angiogenic milieu 
induced by the myocardial matrix, whether indirectly, through its effects on other cell types 
such as immune cells, or directly, by creating a new physical scaffold for vessel infiltration 
or releasing bioactive matricryptic peptides from partial proteolysis of the ECM (23).
Pathway analysis from the microarray data predicted consistent downregulation of apoptosis 
and cell death. Specifically, matrix-injected infarcts expressed higher levels of heme 
oxygenase 1 at 3 days and catalase at 1 week, both of which are stress-induced enzymes that 
reduce reactive oxygen species. In the histological analysis, we demonstrated a trend 
towards a reduction in cardiomyocyte apoptosis in the infarct wall. After an infarct, 
cardiomyocyte death peaks 24 hours after the injury then decreases, but continues to be 
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elevated above baseline levels for at least 12 weeks (24). Therefore, delivery of the 
myocardial matrix could play an important role in salvaging cardiomyocytes that are pre-
apoptotic. Pathway analysis also predicted upregulation of genes involved in mitochondrial 
metabolism. It is well demonstrated that myocardial ischemia reduces substrate oxidation, 
resulting in an increased reliance on glycolysis (25). After matrix injection, we found 
increased expression of PGC-1α, PPARα, PPARβ/δ, and ERRγ. The PGC-1α activates the 
transcription of these nuclear receptors to increase fatty acid uptake, oxidative 
phosphorylation, and mitochondrial biogenesis (26). Expression of PGC-1α targets is known 
to be downregulated in both rodent models and patients with HF (27). We showed an 
increase in PGC-1α in cardiomyocytes in matrix-injected animals. In comparison, injections 
of various bone marrow cells into the infarct myocardium have been associated with 
decreased expression of genes related to mitochondrial function (10,12). Angiotensin-
converting enzyme inhibition using captopril, a common treatment for HF, similarly did not 
rescue changes in fatty acid metabolism (28).
The adult mammalian heart has a limited ability to regenerate, and many recent efforts have 
attempted to enhance this ability post-MI (2). GO analysis suggested activation of terms 
related to heart and cardiovascular system development, which led us to investigate whether 
there was an upregulation of cardiac transcription factors known to play a role in cardiac 
regeneration. We found increased expression of 6 cardiac transcription factors. Of these, 
GATA4, myocardin, Nkx2.5, Tbx5, and Tbx20 are all expressed throughout various stages 
of embryonic cardiogenesis (29), while GATA4, Nkx2.5, and Tbx5 are frequently used to 
identify various CPC subsets (30). Increased expression of MEF and GATA4 were reported 
following injection of bone marrow cells and mononuclear cell secretomes (10,13); 
however, to our knowledge, concomitant elevated transcription of several cardiac 
transcription factors has not been previously reported. A lineage tracing study will however 
be necessary to determine whether the myocardial matrix can induce cardiac regeneration, as 
elevated expressions of these factors can occur during other processes. For example, 
GATA4, myocardin, Nkx2.5, and Tbx20 are expressed by adult cardiomyocytes and are 
required for their survival and function (31–34); cardiac hypertrophy is associated with 
elevated GATA4, MEF2d, and Nkx2.5 (35,36); and cardiac fibroblasts can express high 
levels of GATA4 and Tbx20 (37). We, however, show an increase of 6 transcription factors 
for cardiac development, along with a decrease in cardiac hypertrophy and fibrosis. We also 
found a significant increase in ckit+/tryptase-CPCs in matrix-injected hearts. Previously, the 
myocardial matrix was shown to promote cardiac differentiation of cKit+ CPCs in vitro 
(38). In this study, we found some cKit+ cells coexpressing Nkx2.5, which has been used to 
identify cardiac lineage differentiation in vivo (39). The importance of ckit+ cells in post-
infarct regeneration, however, has been a controversial subject and 2 recent studies arrived 
at opposite conclusions (40,41). Additionally, cKit+ cells may contribute to other effects of 
the myocardial matrix injection, such as neovascularization (41).
Previous studies with myocardial matrix tested delivery at 2 weeks post-MI (8,9). In the 
current study we injected the material 1 week post-MI, demonstrating that the matrix can 
also be effective at an earlier time point. Hemodynamics, which had not been previously 
studied, further demonstrated improvements in LV peak systolic pressure, myocardial 
contractility, and myocardial relaxation. As further evidence that the matrix attenuates 
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negative LV remodeling, decreased hypertrophy was suggested by transcriptional analysis as 
early as 1 week postinjection, and there was a trend towards a reduction in cardiomyocyte 
area and a significant reduction in interstitial fibrosis by 5 weeks.
STUDY LIMITATIONS
Limitations of this study include the use of a small animal model, relatively short time 
points of assessment post-injection, and the more mild ischemia-reperfusion model, which is 
likely more representative of the acute or sub-acute MI population rather than severe 
remodeling in HF patients. While changes in cardiac function were significant in this and a 
previous rat MI study, with similar injections and time points (8), larger increases in 
function were observed in a large animal model where the infarct was more severe, multiple 
injections were performed across the infarct, and cardiac function was examined out to 3 
months post-injection (9). Unlike cells or growth factors, which have had diminished 
efficacy in moving from small to large animals, biomaterials may have the capacity for 
greater improvements in larger animals (42), which is promising for future clinical 
translation. This study also tested a porcine-derived ECM hydrogel in a rat model, which has 
potential for xenograft-elicited inflammation. However, we observed similar improvements 
in a porcine MI model with the porcine-derived material (9), suggesting that the interspecies 
effects are not a major factor. Also, this study mimicked the xenogeneic porcine material 
source being used in an ongoing clinical trial (Clinicaltrials.gov identifier NCT02305602).
CONCLUSIONS
In this study, we demonstrated reduced negative LV remodeling and improved 
hemodynamics following delivery of myocardial matrix 1 week post-MI. We provided both 
transcriptional and histological evidence that the myocardial matrix mediated this by 
inducing various tissue level changes. These results provide further evidence for the promise 
of the myocardial matrix as a therapy to prevent development of HF post-MI.
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ABBREVIATIONS AND ACRONYMS
CPC cardiac progenitor cell
ECM extracellular matrix
EDV end-diastolic volume
IHC immunohistochemistry
LV left ventricle
MI myocardial infarction
qPCR quantitative real-time polymerase chain reaction
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Perspectives
COMPETENCY IN MEDICAL KNOWLEDGE
In animal models, injection of a hydrogel derived from decellularized porcine ventricular 
myocardium attenuated the decline in cardiac function following MI.
TRANSLATIONAL OUTLOOK
Clinical trials are needed to evaluate the safety and efficacy of injectable hydrogels 
prepared from extracellular myocardial matrix in patients with acute MI.
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FIGURE 1. CMR and Hemodynamics Analysis
(A) Cardiac magnetic resonance imaging (CMR) was performed to compare percent changes 
in ejection fraction (EF), end-systolic volume (ESV), and end-diastolic volume (EDV) from 
6 days post-myocardial infarction (MI) (1 day prior to injection) to 6 weeks post-MI (5 
weeks postinjection) at study termination. (B) Left ventricular end-diastolic pressure 
(LVEDP), LV peak systolic pressure (LVPSP), myocardial relaxation (−dP/dtmax), and 
myocardial contractility (+dP/dtmax) were assessed by catheterization prior to euthanasia. *p 
< 0.05; **p < 0.01.
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FIGURE 2. Transcriptomes Cluster Separately at 1 Week Post-injection
Principal component analysis (A) and hierarchical clustering (B) of infarct transcriptomes of 
all samples indicated that global gene expression after myocardial matrix injection is distinct 
from control saline injection by 1 week. (C) Hierarchical clustering of the 2,144 genes 
differentially expressed at 1 week post-injection. RNA from 2 infarcts were combined for 
analysis on 1 microarray chip to reduce biological variability (n = 3 arrays per group, per 
time point). Blue = saline; green = matrix; triangles = 3 days; squares = 1 week.
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FIGURE 3. Inflammatory Response
(A) Expression of genes (red = upregulated; green =downregulated) involved in 
inflammation at 3 days and 1 week. (B) CD68+ staining for macrophages, visualized by 3,3' 
diaminobenzidine (brown) in a myocardial matrix-injected infarct 3 days post-injection. (C) 
Quantification of CD68 staining in the infarct wall from 3 slides at 3 days post-injection. (D) 
Tryptase+ (red) cells in myocardial matrix injected heart at 1 week post-injection; nuclei are 
stained blue with Hoescht 33342. (E) Quantification of all tryptase+ mast cells in the infarct 
wall from 3 slides at 3 days and 1 week post-injection. Scale bar = 50 µm; #p = 0.052, *p < 
0.05.
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FIGURE 4. Blood Vessel Formation
(A) Expression of vessel development genes at 3 days, and growth factors at 1 week. (B) 
Representative images of vessel staining with endothelial cells labeled by von Willebrand 
Factor (vWF; green) and smooth muscle cells labeled with α-smooth muscle actin (red). 
Endothelial cells (C) and arteriole density (D) are quantified within the infarct. Scale bar = 
50 µm; #p < 0.1; *p < 0.05.
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FIGURE 5. Apoptosis
(A) Expression of genes involved in apoptosis at 3 days and 1 week. (B) Examples of 
positive cleaved-Caspase3-expression (red) in α-actinin+ cardiomyocytes (green); nuclei are 
stained blue with Hoescht 33342 (merged image [top] and red-channel only [bottom]). (C) 
Quantification of all cleaved-Caspase3 expressing cardiomyocytes within the border zone of 
3 slides. Scale bar = 50 µm; #p = 0.085.
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FIGURE 6. Myocardial Metabolic Gene Expression
(A) Expression of metabolic genes at 1 week. (B) Example of peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) expression (red) in α-actinin+ 
cardiomyocytes (green) adjacent to the infarct; nuclei are stained blue with Hoescht 33342 
(merged image [top] and red-channel only [bottom]). Thick arrows point to positive 
PGC-1α stained cardiomyocyte nuclei and thin arrows point to negative nuclei. (C) 
Quantification of PGC-1 α + nuclei expression percentage. > 200 cardiomyocytes were 
quantified per heart. Scale bar = 50 µm; **p < 0.01.
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FIGURE 7. Cardiac Development
(A) Expression of genes involved in heart development. (B) Example of cKit+(green)/
tryptase-(red) cells with Hoescht-labeled nuclei (blue) in the myocardial matrix-injected 
infarct after 1 week. (C) Quantification of cKit+/tryptase-cells throughout border zone of 3 
slides at 3 days and 1 week post-injection. Scale bar = 50 µm; #p = 0.067, *p < 0.05.
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FIGURE 8. Hypertrophic Remodeling
(A) Expression of genes involved in hypertrophic response. (B) Representative image of the 
remote myocardium stained with laminin antibody (green) to outline cardiomyocytes and 
Hoescht 33342 to visualize nuclei (blue). (C) Quantification of cardiomyocyte cross-
sectional area, averaged ≥300 cells per heart. (D) Representative Masson’s Trichrome 
staining of interstitial fibrosis (left = saline; right = matrix). (E) Quantification of interstitial 
fibrosis from 5 slides per heart. Scale bar = 50 µm; #p = 0.061; **p < 0.01.
Wassenaar et al. Page 20
J Am Coll Cardiol. Author manuscript; available in PMC 2017 March 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
CENTRAL ILLUSTRATION. Effects of Myocardial Matrix Hydrogel Post-MI: Mechanisms 
Underlying the Functional Benefits
Injection of myocardial matrix 1 week post-myocardial infarction (MI) into the infarcted 
area induced various tissue level changes that reduced negative left ventricular remodeling 
and improved hemodynamics. Altering these key pathways created a pro-regenerative 
environment, potentially preventing or slowing development of heart failure.
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